Efficacy and safety of secukinumab in Chinese patients with psoriatic arthritis: Evidence from a real-world study

Efficacy and safety of secukinumab in Chinese patients with psoriatic arthritis: Evidence from a real-world study

Saved in:

Bibliographic Details
Main Authors:	Xiaohui Zhang, Yuan Chen, Yan Geng, Xuerong Deng, Zhuoli Zhang, Xiangxiang Pan
Format:	Article
Language:	English
Published:	Wolters Kluwer 2024-11-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000003316
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness and safety of secukinumab in axial spondyloarthritis and psoriatic arthritis: A retrospective analysis of its real-world usage from India
by: Sham Santhanam, et al.
Published: (2020-01-01)

Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01)

Interleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritis
by: N. A. Shostak, et al.
Published: (2022-10-01)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
by: V. V. Didenko, et al.
Published: (2021-05-01)

The concordance of swelling/tenderness with ultrasound-detected inflammatory lesions in patients with psoriatic arthritis
by: Xiaoying Sun, et al.
Published: (2025-05-01)

Clinical efficacy of secukinumab in treating sleep disorders in psoriatic patients
by: ZHOU Cuimei, et al.
Published: (2025-07-01)

Secukinumab Persistence in Patients with Psoriatic Arthritis: An Adalimumab-Matched Retrospective Cohort Database Study (FLYWAY)
by: Hideto Kameda, et al.
Published: (2025-03-01)

SUCCESSFUL USE OF AN INTERLEUKIN 17 INHIBITOR (SECUKINUMAB) IN THE TREATMENT OF ISOLATED DESTRUCTIVE ENTHESITIS IN PSORIATIC ARTHRITIS
by: E. E. Gubar, et al.
Published: (2018-11-01)

Secukinumab: A safe option to treat psoriasis and psoriatic arthritis in the presence of interstitial lung disease
by: Raja Natarajan
Published: (2019-01-01)

Superior effect of adalimumab versus secukinumab on ultrasound-confirmed synovitis in psoriatic arthritis: comprehensive evidence from musculoskeletal ultrasound and clinical assessments
by: Yiyi Wang, et al.
Published: (2024-12-01)

Mortality in patients with psoriatic arthritis: a systematic review and meta-analysis
by: Hong Huang, et al.
Published: (2025-08-01)

A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks
by: Suzy van Sanden, et al.
Published: (2025-06-01)

EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS IN REAL CLINICAL PRACTICE
by: E. Yu. Loginova, et al.
Published: (2020-06-01)

RESULTS OF EVALUATING THE EFFICACY OF SECUKINUMAB VERSUS ADALIMUMAB IN TREATING PSORIATIC ARTHRITIS BY USING THE MATCHING-ADJUSTED INDIRECT COMPARISON METHOD
by: T. V. Korotaeva
Published: (2016-12-01)

Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry
by: Giuseppe Lopalco, et al.
Published: (2025-01-01)

The safety and optimal dosage of an interleukin-17A inhibitor (secukinumab) in the treatment of psoriatic arthritis in a patient with concomitant hepatitis C virus infection
by: E. E. Gubar, et al.
Published: (2019-10-01)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
by: Susanne Hartz, et al.
Published: (2020-08-01)

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
by: Philip J Mease, et al.
Published: (2018-08-01)

Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland
by: Anna Felis-Giemza, et al.
Published: (2025-07-01)

Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
by: Ploysyne Rattanakaemakorn, et al.
Published: (2024-11-01)

Golimumab in the treatment of psoriatic arthritis: efficacy and safety
by: Tatiana Viktorovna Korotaeva, et al.
Published: (2015-09-01)

The use of guselkumab in psoriatic arthritis: evidence from real clinical practice
by: N. V. Nekrasova, et al.
Published: (2021-12-01)

Long-Term efficacy and safety analysis of secukinumab in the treatment of pediatric generalized pustular psoriasis: a real-world study
by: Lu Xing, et al.
Published: (2025-12-01)

Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab
by: Jan Brandt-Jürgens, et al.
Published: (2025-06-01)

Psoriatic arthritis in psoriasis: optimizing the current screening system for psoriatic arthritis based on serum data from U.S. and Chinese populations
by: Zheng Lin, et al.
Published: (2024-12-01)

IS PSORIATIC ARTHRITIS REALLY PSORIATIC?
by: Sh. F. Erdes
Published: (2014-12-01)

Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
by: Jiao Wang, et al.
Published: (2025-02-01)

Transitioning from Lupus Low Disease Activity State to remission in systemic lupus erythematosus: real-world evidence
by: Dai Gao, et al.
Published: (2025-03-01)

Comparative efficacy of tofacitinib and adalimumab in patients with psoriatic arthritis in real clinical practice. Data from the Russian nationwide register of patients with psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2021-06-01)

Psoriasis and Psoriatic Arthritis in ChildhoodPsoriasis and Psoriatic Arthritis in Childhood
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
by: T. V. Korotaeva, et al.
Published: (2019-05-01)

THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2016-12-01)

Use of the interleukin-17A inhibitor secukinumab in psoriatic arthritis: a subanalysis of the Russian population in the international randomized clinical trials FUTURE 1 and FUTURE 2
by: T. V. Korotaeva, et al.
Published: (2017-04-01)

Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study
by: Ece Erbağcı, et al.
Published: (2025-01-01)

Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study
by: Bente Glintborg, et al.
Published: (2025-07-01)

The efficacy and safety of apremilast in patients with psoriatic arthritis concurrent with comorbidity in clinical practice
by: E. Yu. Loginova, et al.
Published: (2019-07-01)

Early psoriatic arthritis
by: E. Y. Loginova, et al.
Published: (2008-12-01)

Nail disease in psoriatic arthritis. Data from the Russian Psoriatic Arthritis Registry
by: E. E. Gubar, et al.
Published: (2021-10-01)

Correction: Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and psoriatic arthritis: a nationwide cohort study
Published: (2025-08-01)

OPTIMIZING THE DIAGNOSIS, A MONITORING AND TREATMENT SYSTEM FOR PSORIATIC ARTHRITIS IN REAL PRACTICE: GENERAL PRINCIPLES FOR ORGANIZING AN ALL-RUSSIAN REGISTER OF PATIENTS WITH PSORIATIC ARTHRITIS
by: T. V. Korotaeva, et al.
Published: (2019-09-01)